Ngôn ngữ:

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

The New England journal of medicine, 2020-10, Vol.383 (15), p.1413-1424 [Tạp chí có phản biện]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2022190 ;PMID: 32865377

Tài liệu số/Tài liệu điện tử

Gửi đến

Nhan đề:
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Tác giả: Packer, Milton ; Anker, Stefan D ; Butler, Javed ; Filippatos, Gerasimos ; Pocock, Stuart J ; Carson, Peter ; Januzzi, James ; Verma, Subodh ; Tsutsui, Hiroyuki ; Brueckmann, Martina ; Jamal, Waheed ; Kimura, Karen ; Schnee, Janet ; Zeller, Cordula ; Cotton, Daniel ; Bocchi, Edimar ; Böhm, Michael ; Choi, Dong-Ju ; Chopra, Vijay ; Chuquiure, Eduardo ; Giannetti, Nadia ; Janssens, Stefan ; Zhang, Jian ; Gonzalez Juanatey, Jose R ; Kaul, Sanjay ; Brunner-La Rocca, Hans-Peter ; Merkely, Bela ; Nicholls, Stephen J ; Perrone, Sergio ; Pina, Ileana ; Ponikowski, Piotr ; Sattar, Naveed ; Senni, Michele ; Seronde, Marie-France ; Spinar, Jindrich ; Squire, Iain ; Taddei, Stefano ; Wanner, Christoph ; Zannad, Faiez
Chủ đề: Aged ; Benzhydryl Compounds - adverse effects ; Benzhydryl Compounds - therapeutic use ; Cardiology and cardiovascular system ; Cardiovascular diseases ; Cardiovascular Diseases - mortality ; Cardiovascular Diseases - prevention & control ; Congestive heart failure ; Death ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - complications ; Disease Progression ; Double-Blind Method ; Drug dosages ; Ejection fraction ; Female ; Genital tract ; Glomerular filtration rate ; Glomerular Filtration Rate - drug effects ; Glucosides - adverse effects ; Glucosides - therapeutic use ; Heart failure ; Heart Failure - complications ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; Hospitalization ; Hospitalization - statistics & numerical data ; Human health and pathology ; Humans ; Kidney diseases ; Life Sciences ; Male ; Middle Aged ; Patient outcomes ; Peptides ; Proportional Hazards Models ; Quality of life ; Renal Insufficiency, Chronic - complications ; Sodium-Glucose Transporter 2 Inhibitors - adverse effects ; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use ; Statistical analysis ; Stroke Volume
Là 1 phần của: The New England journal of medicine, 2020-10, Vol.383 (15), p.1413-1424
Mô tả: Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of cardiovascular death or hospitalization for heart failure than those who received placebo.
Nơi xuất bản: United States: Massachusetts Medical Society
Ngôn ngữ: English
Số nhận dạng: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa2022190
PMID: 32865377
Nguồn: ProQuest One Psychology
Hyper Article en Ligne (HAL) (Open Access)
MEDLINE
ProQuest Central

Trở lại danh sách kết quả


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2022190 ;PMID: 32865377

Đang tìm Cơ sở dữ liệu bên ngoài...